Manages chronic stable angina and angina due to coronary artery spasm. ANDA 219253, held by Zydus Lifesciences. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 219253 (Diltiazem Hydrochloride), held by Zydus Lifesciences, was first approved by FDA on Aug 8, 2025, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 8, 2025 | Original application | Approved | None posted |
| Diltiazem Hydrochloride30MG · tablet;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride60MG · tablet;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride90MG · tablet;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride120MG · tablet;oral | Diltiazem Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters